Success Story: EB1A Approved! We Helped a Molecular Biology Researcher Specializing in Immunity and Cancer Mechanisms Secure Success
Client’s Testimonial:
“Thank you for your team's wonderful work.”
On January 29th, 2026, we received another EB-1A (Alien of Extraordinary Ability) approval for an Assistant Instructor in the Field of Molecular Biology (Approval Notice).
General Field: Molecular Biology
Position at the Time of Case Filing: Assistant Instructor
Country of Origin: China
State of Residence at the Time of Filing: Texas
Approval Notice Date: January 29th, 2026
Processing Time: 18 months (Premium Processing Upgrade Requested)
Case Summary:
We are pleased to announce the I-140 EB1A (Alien of Extraordinary Ability) approval for an accomplished researcher in the field of molecular biology. With a carefully structured petition that highlighted original contributions, independent reliance by the research community, and sustained peer trust, the case was approved based on a clear, objective record of influence in immunity and cancer mechanisms.
Academic Achievements and Professional Recognition
The client holds a Ph.D. in zoology and is an established expert in molecular biology, with specialized expertise in immunity and cancer mechanisms. The petition emphasized the client’s investigation of the several genes to support advances in breast and ovarian cancer treatment research, positioning this work as both scientifically rigorous and directly relevant to high-impact biomedical priorities.
At the time of filing, the client had authored 8 peer-reviewed journal articles (including 3 first-authored publications) and 1 first-authored book chapter. The client’s work had been cited 185 times. We did not present these figures as automatically sufficient. Instead, we explained how an adjudicator could interpret the citation record as evidence of independent reliance, meaning that other researchers have used the client’s findings and methods to inform and validate their own work. We also provided context showing that at least one publication achieved notably strong citation performance compared to others in its field for its publication year, reinforcing that the influence was not only present but meaningfully above typical expectations.
The petition further documented that the client completed at least 30 peer reviews. We framed this as a key trust signal because journals typically invite reviewers who have demonstrated expertise and sound judgment, and because peer review reflects the field’s reliance on the client to help evaluate the work of other experts.
In addition, the petition included evidence that the client’s work received support from major funding sources, including the U.S. National Institutes of Health (NIH), the Human Frontiers Science Program (HFSP), the New Jersey Health Foundation (NJHF), the Max and Minnie Tomerlin Voelcker Fund, the National Key R&D Programmes of China, the National Natural Science Foundation of China (NSFC), the Ministry of Agriculture of China, and the New Jersey Commission on Cancer Research (NJCCR). We presented this funding history as objective reinforcement that the client’s research direction has been recognized and supported by established research sponsors.
The petition also described that the client is currently employed as a postdoctoral researcher in the United States, continuing work aligned with molecular biology and cancer-related research. This helped show continuity between the client’s established expertise and the work the client intends to continue pursuing in the United States.
Expert Endorsements
The petition was supported by 4 letters of recommendation from leading experts in the field, including independent authorities familiar with the client’s work through publications. These letters were used to corroborate the objective evidence and to translate specialized molecular biology contributions into clear, field-facing significance.
“Therefore, [Client’s] work is an asset for hundreds of thousands of American women at risk of developing breast cancer.”
The ResultUSCIS approved the EB1A petition, reflecting a persuasive showing that the client has reached the small percentage at the top of the field through original contributions of major significance, sustained independent reliance demonstrated through citations, and a trusted peer review service. We are proud to have supported this successful outcome and look forward to the client’s continued contributions to advancing molecular biology research related to immunity and cancer mechanisms in the United States.